| viXra.org > Biochemistry > 2004 |
 |
 |
| viXra.org > Biochemistry > 2004 |
|
|
[6] viXra:2004.0709 [pdf] submitted on 2020-04-30 13:32:53
Authors: Boulay Jean-Yves
Comments: 23 Pages. Paper was presented on Symmetry Festival 2006
This study describes numerous phenomena of symmetry in the distribution of the amino acids in the genetic code
table. These phenomena consist to arithmetical arrangements of sets of modules numbers or/and of protons numbers which are counted in each of the 20 amino acids used by the standard genetic code. In this present article, is specifically investigated the molecular modules
system of Professor Sergei Petoukhov.
Category: Biochemistry
[5] viXra:2004.0589 [pdf] submitted on 2020-04-25 09:06:36
Authors: Andrei Lucian Dragoi
Comments: (ASEA in DMD 3rd case preprint - v.1.0 - 24.04.2020 - 10 A4 pages)
This paper argues that “ASEA redox Supplement” (ARS) may show comparable or even stronger beneficial effects (with less or none adverse effects) than corticosteroids in children with Duchenne Muscular Dystrophy (DMD) and Becker muscular dystrophy (BMD). This paper presents a third case report on the effects of an ionized “saline water” called “ASEA redox Supplement®” (ARS) oral solution in a ~3-year-old boy with DMD from town Slobozia [URL2], Romania. In vitro studies showed that ARS is a very potent selective NRF2 activator, thus a very potent (indirect) antioxidant and cytoprotective: the studies conducted in vivo also support this main pharmacological mechanism of ARS, with no toxicity up to high doses, in contrast with the much more toxic corticosteroids. From the first months of ARS treatment, the main rhabdomyolysis markers (with very high initial serum levels) dropped significantly, with no found toxicity until the present. Before starting adjuvant therapy with oral ARS, this boy-patient was already prescribed by his attending neurologist a combined therapy with: L-carnitine (1g/day) & Vitamin D3 (1000IU/day) & calcium-magnesium oral supplement (5ml/day) & plant-extracts hepatoprotective syrup (5ml/day) & coenzyme Q10 (30mg/day) from the last week of February 2019 (thus from approximately 5 months earlier than the moment in which ARS therapy was initiated). This previous combined therapy of dietary supplements (DSs) also showed a promising decrease in rhabdomyolysis serum markers (RSMs) (which is also an important fact with implications for other children with DMD who may potentially benefit from this combined set of DSs): however, when the calcium-magnesium oral supplement was replaced by a combination of ARS (30ml/day ~ 2.5ml/kg/day) & omega-3 fatty acids (185mg/day with a DHA: EPA ratio of approx. 5-to-1) from August 1st, 2019, the RSMs decrease was quite spectacular (when compared to the anterior decrease) when measured in December 2nd, 2019 at “Victor Gomoiu” Pediatric Hospital (from Bucharest, Romania). This paper continues the work of other past articles/preprints of the same author.
Category: Biochemistry
[4] viXra:2004.0448 [pdf] replaced on 2020-04-18 19:04:10
Authors: Shazia Tahira
Comments: 18 Pages.
Pancreatic cancer is one of the most lethal cancer and there is innate resistance to standard chemotherapy regimens in pancreatic cancer. Gemcitabine was approved in 1996 for the chemotherapeutic treatment of metastatic pancreatic cancer. FOLFIRINOX (fluorouracil, leucovorin, irinotecan, oxaliplatin) and gemcitabine plus nab-paclitaxel combination therapies have shown superiority to gemcitabine monotherapy but are more toxic than gemcitabine monotherapy. Therefore, gemcitabine monotherapy is still one of the standard treatments for pancreatic cancer for patients who can’t tolerate the toxicity of other chemotherapeutic regimens. The effectiveness of standard chemotherapeutic drugs is limited in pancreatic cancer due to drug resistance, and undesirable side effects. There is a likelihood that the combination of standard chemotherapy with natural compounds having anti-cancer potential like curcumin will increase the effectiveness of treatment as well as reduce the toxic side effects of standard chemotherapeutic agents. Curcumin is a polyphenolic compound isolated from the rhizome of Curcuma longa (turmeric) and is considered a promising anticancer agent. Here, a review is presented about the potential use of curcumin with standard chemotherapy in pancreatic cancer as there is a potential in different combination regimens of curcumin in pancreatic cancer to increase median survival in pancreatic cancer in comparatively less toxic, novel ways. Also, curcumin combination chemotherapy may lead to the improvement of cancer and chemotherapy-related symptoms. The poor bioavailability of curcumin has been the major obstacle for its clinical application. To overcome this problem, several curcumin preparations have been developed including cost-effective preparation methods to increase the bioavailability of curcumin. Different studies have shown that gemcitabine curcumin combination regimen can effectively increase survival with less toxicity in patients who are resistant to gemcitabine and can’t even tolerate the toxicity of other chemotherapeutic combination regimens. Although clinical trials are needed, Paclitaxel and curcumin cobound albumin nanoparticles also have the potential to become another alternative chemotherapeutic regimen for pancreatic cancer. For those patients who can tolerate gemcitabine paclitaxel regimen toxicity, there can also be a future possibility of using paclitaxel and curcumin cobound albumin nanoparticles with gemcitabine and this triple therapy may have enhanced therapeutic effects with comparatively less toxic effects. Curcumin has shown its effectiveness with the constituents of FOLFIRINOX in other types of cancers, therefore there is a need for curcumin FOLFIRINOX combined clinical trials in pancreatic cancer as curcumin has the potential to increase the effectiveness of FOLFIRINOX as well as reduce its toxic side effects.
Category: Biochemistry
[3] viXra:2004.0370 [pdf] submitted on 2020-04-15 03:40:43
Authors: George Rajna
Comments: 70 Pages.
Computational chemist Mahmoud Moradi will develop enhanced, 3-D simulations of the molecular dynamics of coronavirus spike glycoproteins to gain better understanding of how the virus binds to human cells. [41] According to the Centers for Disease Control and Prevention, common human coronaviruses usually cause mild to moderate upper-respiratory tract illnesses, like the common cold. [40] When diseases reinforce each other, they rapidly accelerate through the population, then fizzle out as they run out of new hosts. [39] It's no coincidence that some of the worst viral disease outbreaks in recent years-SARS, MERS, Ebola, Marburg and likely the newly arrived 2019-nCoV virus-originated in bats. [38] An interdisciplinary team of researchers at Colorado State University has used computational chemistry, biochemistry and virology to uncover new information on how viruses such as West Nile, dengue and Zika replicate. [37] David Baker, Professor of Biochemistry and Director of the Institute for Protein Design at the University of Washington will speak about how algorithmic processes such as de novo design predict protein structures, protein folding mechanisms, and new protein functions. [36] A research team at Kobe University has developed a method of artificially controlling the anchorage position of target proteins in engineered baker's yeast (Saccharomyces cerevisiae). [35] Scientists have found a new way to home in on the proteins covering a particular cell's surface. The feat offers insight into how brain cells form intricate networks during development. [34]
Category: Biochemistry
[2] viXra:2004.0127 [pdf] submitted on 2020-04-06 07:51:35
Authors: Arturo Tozzi
Comments: 6 Pages.
We hypothesize that the increased expression of the SUSD1 host gene caused by Coronavirus infection may contribute to the lower respiratory tract cytokine storm that makes severe acute respiratory syndrome a life-threatening disease.
Category: Biochemistry
[1] viXra:2004.0087 [pdf] replaced on 2020-11-15 11:23:50
Authors: M.S. Shukor, M.Y. Shukor
Comments: 12 Pages.
COVID-19 is caused by the coronavirus SARS-CoV-2 and is now a pandemic affecting humans at the global scale. Researchers are still trying to find a cure and a vaccine to fight the pandemic. Drug-based cure and vaccines are overwhelmingly virus-specific and newer drugs and vaccines are needed to resist new novel viral infections and resistant strains. The use of natural-based therapies including herbal remedies and plant-based extracts to fight viral infections is an ongoing work which has accelerated to a fast pace due to the severity of the current pandemic. Several approaches have been carried out including the use of traditional Chinese herbal medicines. Papaya leaves extract (PLE) has been intensively studied for its antiviral, immunomodulatory and cytokine storm-alleviating properties in dengue-afflicted patients. These properties, especially PLE ability to inhibit TNF-alpha, hold promise for its capability as a possible weapon to fight COVID-19. This work attempts to put up a case for PLE as a conceivable weapon to fight COVID-19.
Category: Biochemistry
| Third-Party Links: |
|